Protagenic Therapeutics- Warrants (13/04/2025) P/E Ratio

Protagenic Therapeutics- Warrants (13/04/2025) (PTIXW) currently reports a P/E ratio of 0.31. That is below the Industrials sector average of 28.36. Use the charts on this page to explore Protagenic Therapeutics- Warrants (13/04/2025)'s P/E ratio history and peer comparisons.

Protagenic Therapeutics- Warrants (13/04/2025)'s P/E ratio of 0.31 is lower than the Industrials sector average of 28.36. That is roughly 98.9% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

The P/E ratio is a valuation multiple that relates Protagenic Therapeutics- Warrants (13/04/2025)'s market price to a fundamental measure such as earnings, sales, or book value. At 0.31, PTIXW can look expensive or cheap only in context — versus its own history, growth rate, and Industrials peers. Higher multiples often price in stronger expected growth; lower ones can signal value or concern.

Start with the current P/E ratio of 0.31, then check the historical chart for trend and the peer comparison chart for relative positioning. The Industrials average is 28.36. From there, open related valuation or income-statement pages for Protagenic Therapeutics- Warrants (13/04/2025), and consider following PTIXW for alerts when major investors trade the stock.

Protagenic Therapeutics- Warrants (13/04/2025) is classified in the Industrials sector. On P/E ratio, it currently shows 0.31 versus a sector average near 28.36. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Industrials are usually more informative than comparing PTIXW with unrelated industries.